Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARγ gene variants

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue 8, 2008, Pages 481-486

  Knebel, B ^a   Janssen, O E ^b   Hahn, S ^c   Jacob, S ^a   Gleich, J ^a   Kotzka, J ^a   Muller Wieland, D ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ENDOKRINOLOGIKUM HAMBURG   (Germany)

^c Praxis fur Endokrinologie   (Germany)

^d Diabetes Research Group   (Germany)

Author keywords

Inflammation; Insulin resistance; Metabolic syndrome; PCCOS; PPAR

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA POLYMORPHISM; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INSULIN SENSITIVITY; NUCLEOTIDE SEQUENCE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL; CYTOKINES; FEMALE; GENE FREQUENCY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; POLYCYSTIC OVARY SYNDROME; PPAR GAMMA; VARIATION (GENETICS);

EID: 54549096932     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1058085     Document Type: Article

References (40)

1. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001;56: 295-308
2. Salesi M, Bravo-Vera R, Sheikh A, Gouller A, Poretzky L. Pathogenesis of the polycystic ovary syndrome: What is the role of obesity? Metabolism 2004; 53: 358-376
3. O'Meara NM, Blackman JD, Ehrmann DA. Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1241-1247
4. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236
5. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 1999; 16: 1255-1260
6. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev 1999; 20: 649-688
7. Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun 1997; 233: 756-759
8. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000; 14: 1293-1307
9. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-472
10. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002; 51: 2341-2347
11. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary sindrome with the Pro12Ala polymorphism in the PPARγ gene. J Clin Endocrinol & Metab 2002; 87: 772-775
12. Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, Tapanainen JS, Laakso M. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod 2003; 18: 540-543
13. Oil F, Matarese G, Blase S Di, Palomba S, Labella D, Sanna V, Savastano S, Zullo F, Colao A, Lombardi G. Exon 6 and 2 peroxisome proliferator-activated receptorγ polymorphisms in polycystic ovary sindrome. J Clin Endocrinol & Metab 2003; 88: 5887-5892
14. Altshuler D, Hirschhorn JN, Klannemark M, Lindgreen CM, Vohl MC, Nemesh J, Lane CR, Schaffer SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80
15. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J. Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARγamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287
16. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deep SS, Auwerx J, Uusitupa M, Laasko M. Two polymorphisms in the peroxisome proliferators-activated receptor-gamma gene are associated with severe overweigt among obese women. J Clin Endocrinol Metab 1999; 84: 3708-3712
17. Schaffler A, Barth N, Schmitz G, Zieht B, Palitzsch KD, Scholmerich J. Frequency and significance of Pro12 Ala and Pro115Gln polymorphisms in gene for peroxisome proliferation-activated receptor - gamma regarding metabolic parameters in a Caucasian cohort. Endocrine 2001; 14: 369-373
18. Ek J, Andersen G. Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001; 44: 1170-1176
19. Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W, Balletshofer B, Machicao F, Rett K, Haring HU. The PPARγamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 2000; 32: 413-416
20. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999; 48: 1466-1468
21. Semple RK, Chatterjee VX, O'rahilly S. PPARgamma and human metabolic disease. J Clin Invest 2006: 116: 581-589
22. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
23. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459
24. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002; 13: 413-421
25. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48: 437-441
26. Kelly CC, Lyall H, Petrie JR, Gould GW Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-2455
27. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in premenopausal women. Diabetologia 2003; 46: 625-633
28. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-532
29. Puder JJ, Varga S, Kraenzlin M, Geyter C De, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005: 90: 6014-6021
30. Yao Q, Nordfors L, Axelsson J, Heimburger O, Qureshi AR, Barony P, Lindholm B, Lonnqvist F, Schalling M, Stenvinkel P. Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 2005; 182: 105-111
31. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, Knebel B, Muller-Wieland D, Mann K, Janssen OE. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol 2005; 62: 573-579
32. Jovanovic DV, Battista JA Di, Martel-Peiletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998; 160: 3513-3521
33. Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M, Mellick LB. Cytokine response to diabetic ketoacidosis and its treatment. Clin Immunol 2003; 108:175-181
34. Zozulinska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 1999; 42: 117-118
35. Esposito K, Marfella R, Ciotola M, Palo C Di, Giugliano F, Giugliano G. DÁrmiento M, DÁndrea F, Giugliano D. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. JAMA 2004; 292: 1440-1446
36. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003; 100: 125-130
37. Weitzmann MN, Pacifici R. Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 2006; 1068: 256-274
38. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86
39. Fajas L, Debril MB, Auwerx J. PPAR gamma: an essential role in metabolic control. Nutr Metab Cardiovasc Dis 2001; 11: 64-69
40. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Rettig A, Renn W, Haring HU. The silent PPAR gamma exon 6 CAC (His) >CAT (His) polymorphism does not affect the plasma leptin levels in a collective of first degree relatives of type 2 diabetes patients from South West Germany. Exp Clin Endocrinol Diabetes 2000; 108: 341-346